Video Coming Soon
規制当局やスポンサー企業は、モデルを活かした医薬品開発 (MIDD) の重要性が強く認識しています。このため、当社は本分野における将来の専門家育成に世界規模で注力しています。その目的の達成を目指して、当社は世界各国の中核的アカデミック研究拠点 (Centres of Excellence, COE) における著名な科学者と提携しています。This year, our Centers of Excellence will present our webinar series.
2022 年 5 月 24 日 – Dissolution Models using Phoenix: application to IVIVC, usual problems and mistakes
24 May Dr. Jean Michel Cardot will be speaking on Dissolution Models using Phoenix: application to IVIVC, usual problems and mistakes. Dissolution results correspond to percent dissolved or concentration vs time. Dissolution profiles could be driven by API or by formulation characteristics.
2022 年 8 月 16 日 – Leveraging an Opportunistic Study Design to Model PK in Pregnancies Complicated by Systemic Lupus
Pregnant women often have to take medication during their pregnancies. It’s important to understand how pregnancy can alter a drug’s pharmacokinetics. Register for this webinar with Duke University’s Dr. Stephen Balevic to learn about his research on leveraging an opportunistic study design to model pharmacokinetics for a commonly used drug in pregnancies complicated by systemic lupus.
2022 年 9 月 20 日 – Pharmacokinetics of Midazolam and Metabolites in Critically Ill Pediatric Population
Dr. Leonid Kagan from Rutgers University will be presenting on 20 September. His topic is “Pharmacokinetics of Midazolam and Metabolites in Critically Ill Pediatric Population”. The webinar will focus on developing a population model for describing plasma pharmacokinetics and urinary excretion of midazolam and four metabolites in critically ill children. The model included maturation of elimination pathways (renal, CYP-mediated metabolism and glucuronidation) and effects of therapeutic hypothermia.
2022 年 10 月 4 日 – Lidocaine clearance during liver resection for living donor transplanton
The University of Colorado School of Medicine’s Dr. Thomas Henthorn will talk about Lidocaine clearance during liver resection for living donor transplanton 4 October. He will discuss a NLME pharmacokinetic model for lidocaine that was constructed from the plasma lidocaine concentration versus time data.
2022 年 10 月 18 日 – The Physiological Basis of Comparative Pharmacokinetics
Utrecht University’s Dr. Ronette Gehring will close out the series on 18 October speaking on The Physiological Basis of Comparative Pharmacokinetics. Veterinary pharmacology has a long history of conducting studies to empirically describe the pharmacokinetics of drugs in a wide range of different animal species. These data are valuable for informing dosage regimens in the target animal species, but they are also contribute to a better understand the physiological basis for inter- and intra-species differences. More recently, physiologically-based pharmacokinetic (PBPK) models have been applied to describe and extrapolate pharmacokinetics between species. PBPK models are complex, resource intensive and have many parameters of which the values are not always known a priori. Another approach is to use more minimalistic, semi-mechanistic models to explore how changes in anatomy and physiology might explain differences in the pharmacokinetics of a drug. In this webinar we will explore how this can be done in Phoenix NLME®.
2022 年 11 月 1 日 – Whole-Body Pharmacokinetics of MMAE and MMAE-based ADC in Mice
Hsuan Ping Chang of The State University of New York – Buffalo speaking on Whole-Body Pharmacokinetics of MMAE and MMAE-based ADC in Mice.